Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cytotoxic Chemotherapy Clear all
Recruiting Phase 1 Interventional

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

NCT06914479
View directory record Official record
Conditions
Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm
Interventions
Ad-hCMV-Flt3L, Ad-hCMV-TK, Biospecimen Collection, Magnetic Resonance Imaging, Survey Administration, Tumor Resection, Valacyclovir
Genetic · Procedure · Other + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 39 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 28, 2026, 8:11 PM EDT
Terminated Phase 3 Interventional

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT01697072
View directory record Official record
Conditions
Gastric Cancer
Interventions
Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

NCT00090896
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 28, 2026, 8:11 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

NCT04319224
View directory record Official record
Conditions
Cancer
Interventions
Vopratelimab, Ipilimumab, Nivolumab
Drug
Lead sponsor
Jounce Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 28, 2026, 8:11 PM EDT
Terminated Phase 2 Interventional Results available

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

NCT02087241
View directory record Official record
Conditions
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions
AZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

NCT02891278
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sertraline, Cytosine arabinoside, allogeneic stem cell transplantation
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Early Phase 1 Interventional

Viral Specific T Cell Therapy for COVID-19 Related Pneumonia

NCT04742595
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 28, 2026, 8:11 PM EDT
Recruiting Phase 2 Interventional

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT07510334
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Nivolumab, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 28, 2026, 8:11 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

NCT02785952
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1201
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 28, 2026, 8:11 PM EDT
Terminated Phase 2 Interventional Results available

Treatment With Nab-paclitaxel in Cutaneous SCC

NCT02076243
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 28, 2026, 8:11 PM EDT
Recruiting Phase 1 Interventional

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

NCT07128680
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Dietary Supplement · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 28, 2026, 8:11 PM EDT
Recruiting Phase 2 Interventional

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

NCT05887609
View directory record Official record
Conditions
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine-gynx, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
6
States / cities
Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM

NCT01109095
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM)
Interventions
HER.CAR CMV-specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases

NCT01447056
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoproliferative Disorder, Nasopharyngeal Carcinoma, Leiomyosarcoma, Severe Chronic Active EBV (SCAEBV)
Interventions
LMP specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 28, 2026, 8:11 PM EDT
Not listed No phase listed Observational

Use of Immunosuppressive Therapy for Sarcoidosis

NCT02356445
View directory record Official record
Conditions
Sarcoidosis
Interventions
Cytotoxic drug
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 90 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 28, 2026, 8:11 PM EDT
Terminated Early Phase 1 Interventional

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

NCT01730157
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

NCT01378091
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lenalidomide, Docetaxel, Prednisone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 28, 2026, 8:11 PM EDT
Recruiting Early Phase 1 Interventional

Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

NCT04293042
View directory record Official record
Conditions
BK Polyomavirus
Interventions
BK-virus specific CTLs
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Weeks to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

NCT04518046
View directory record Official record
Conditions
Clear-Cell Renal Cell Carcinoma
Interventions
Sitravatinib, Nivolumab, Ipilimumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique
Biological · Genetic · Other
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 28, 2026, 8:11 PM EDT
Completed No phase listed Observational

Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy

NCT01789983
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer
Interventions
Walk With Ease Program, Collect Blood, GA and Other Survey Tools
Behavioral · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 28, 2026, 8:11 PM EDT
Recruiting Phase 3 Interventional

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

NCT07383441
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration
Drug · Procedure · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
41
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT01585194
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 28, 2026, 8:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

NCT02661282
View directory record Official record
Conditions
Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions
Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide, Therapeutic Conventional Surgery
Biological · Other · Drug + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 28, 2026, 8:11 PM EDT